Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation
暂无分享,去创建一个
M. Hayakari | T. Habuchi | M. Miura | S. Satoh | T. Niioka | H. Kagaya | M. Saito*
[1] T. Habuchi,et al. No pharmacokinetic interactions between mycophenolic acid and tacrolimus in renal transplant recipients , 2008, Journal of clinical pharmacy and therapeutics.
[2] T. Habuchi,et al. Influence of Lansoprazole and Rabeprazole on Mycophenolic Acid Pharmacokinetics One Year After Renal Transplantation , 2008, Therapeutic drug monitoring.
[3] S. Uemoto,et al. Interaction between tacrolimus and lansoprazole, but not rabeprazole in living-donor liver transplant patients with defects of CYP2C19 and CYP3A5. , 2008, Drug metabolism and pharmacokinetics.
[4] A. B. Ruzilawati,et al. Genetic polymorphisms of CYP3A4: CYP3A4*18 allele is found in five healthy Malaysian subjects. , 2007, Clinica chimica acta; international journal of clinical chemistry.
[5] Kyungsoo Park,et al. Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects. , 2007, British journal of clinical pharmacology.
[6] T. Habuchi,et al. Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients , 2007, Biopharmaceutics & drug disposition.
[7] B. Vinet,et al. Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients , 2006, Pharmacogenetics and genomics.
[8] Robert E. Smith,et al. Delayed gastric ulcer healing associated with sirolimus. , 2006, Transplantation.
[9] T. Habuchi,et al. Determination of rabeprazole enantiomers and their metabolites by high-performance liquid chromatography with solid-phase extraction. , 2006, Journal of pharmaceutical and biomedical analysis.
[10] Leif Bertilsson,et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants , 2006, Clinical pharmacology and therapeutics.
[11] D. Hesselink,et al. The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression? , 2005, Pharmacogenomics.
[12] T. Habuchi,et al. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. , 2005, Transplantation proceedings.
[13] T. Habuchi,et al. Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers , 2005, Xenobiotica; the fate of foreign compounds in biological systems.
[14] B. Suwelack,et al. Resolution of severe MMF-related gastrointestinal adverse events following conversion to enteric-coated mycophenolate sodium. , 2005, Transplantation.
[15] Jun He,et al. CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population. , 2005, Clinica chimica acta; international journal of clinical chemistry.
[16] N. Ohkohchi,et al. Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations , 2004, The Journal of pharmacy and pharmacology.
[17] K. Shu,et al. Risk factors for peptic ulcer disease in renal transplant patients--11 years of experience from a single center. , 2004, Clinical nephrology.
[18] M. Miura,et al. Simultaneous determination of lansoprazole enantiomers and their metabolites in plasma by liquid chromatography with solid-phase extraction. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[19] O. Ogawa,et al. Lansoprazole—Tacrolimus Interaction in Japanese Transplant Recipient with CYP2C19 Polymorphism , 2004, The Annals of pharmacotherapy.
[20] C. Staatz,et al. Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation , 2004, Clinical pharmacokinetics.
[21] W. Weimar,et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR‐1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus , 2003, Clinical pharmacology and therapeutics.
[22] J. Azuma,et al. Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. , 2002, Pharmacogenetics.
[23] Ann Daly,et al. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. , 2002, Pharmacogenetics.
[24] M. Homma,et al. Effects of lansoprazole and rabeprazole on tacrolimus blood concentration: case of a renal transplant recipient with CYP2C19 gene mutation. , 2002, Transplantation.
[25] U. Christians,et al. Mechanisms of Clinically Relevant Drug Interactions Associated with Tacrolimus , 2002, Clinical pharmacokinetics.
[26] H. Mohrenweiser,et al. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. , 2001, The Journal of pharmacology and experimental therapeutics.
[27] A Johnston,et al. Limited Sampling Strategies for Estimating Cyclosporin Area Under the Concentration–Time Curve: Review of Current Algorithms , 2001, Therapeutic drug monitoring.
[28] M. Lai,et al. Novel mutations of CYP3A4 in Chinese. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[29] T. Suzuki,et al. A rapid and simple detection of genetic defects responsible for the phenotypic polymorphism of cytochrome P450 2C19. , 1999, Biological & pharmaceutical bulletin.
[30] S. Higuchi,et al. Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: possible effect of age, liver disease and length of therapy. , 1999, British journal of clinical pharmacology.
[31] C. Nakamura,et al. Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects , 1997, European Journal of Clinical Pharmacology.
[32] J. Goldstein,et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. , 1997, Pharmacogenetics.
[33] L. Bertilsson,et al. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. , 1996, Pharmacogenetics.
[34] J. Balian,et al. Determination of CYP2C19 phenotype in black Americans with omeprazole: Correlation with genotype , 1996, Clinical pharmacology and therapeutics.
[35] A. D. Rodrigues,et al. Identification of the human P450 enzymes involved in lansoprazole metabolism. , 1996, The Journal of pharmacology and experimental therapeutics.
[36] C. Bonfils,et al. Oxidative metabolism of lansoprazole by human liver cytochromes P450. , 1995, Molecular pharmacology.
[37] D. Dunn,et al. Incidence, complications, treatment, and outcome of ulcers of the upper gastrointestinal tract after renal transplantation during the cyclosporine era. , 1995, Journal of the American College of Surgeons.
[38] L. Bertilsson,et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S‐mephenytoin , 1992, Clinical pharmacology and therapeutics.
[39] I. Yamatsu,et al. Inhibitions of acid secretion by E3810 and omeprazole, and their reversal by glutathione. , 1991, Biochemical pharmacology.
[40] H. Satoh,et al. Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells. , 1990, The Journal of pharmacology and experimental therapeutics.
[41] N. Takeguchi,et al. The potency of substituted benzimidazoles such as E3810, omeprazole, Ro 18-5364 to inhibit gastric H+, K(+)-ATPase is correlatedwith the rate of acid-activation of the inhibitor. , 1990, Biochemical pharmacology.
[42] R. Branch,et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations , 1985, Clinical pharmacology and therapeutics.
[43] G. Wilkinson,et al. Mephenytoin hydroxylation deficiency in Caucasians: Frequency of a new oxidative drug metabolism polymorphism , 1984, Clinical pharmacology and therapeutics.